Stonegate Capital Partners Initiates Coverage on NU Skin Enterprises Inc. with Positive Outlook

Stonegate Capital Partners has initiated coverage on NU Skin Enterprises Inc. (NYSE: NUS), spotlighting the company's robust financial results and strategic initiatives aimed at fostering growth. NU Skin reported revenue, adjusted Net Income, and adjusted EPS of $386.1M, $21.1M, and $0.43, respectively, with revenue at the high end of the guidance range. The Rhyz Manufacturing segment notably achieved a 17% year-over-year revenue growth, and EPS significantly outpaced guidance, showcasing the company's operational efficiency and market strength.

The company's strategic initiatives, including expansion into India and the launch of the Prysm iO wellness device, are poised to be significant growth drivers. The India market entry is on schedule for pre-opening activities in 4Q25, with a full launch anticipated by mid-2026. The Prysm iO, an AI-powered wellness assessment device, represents a technological leap forward, offering personalized product recommendations on an unprecedented scale.

Despite a year-over-year decline in sales leaders, paid affiliates, and customers, NU Skin demonstrated strong revenue growth in Latin America, attributed to its scalable digital-first model. The company's solid balance sheet, with $264.2M in cash on hand and a positive net cash position, provides the flexibility needed to execute its strategic initiatives effectively.

NU Skin has tightened its FY25 revenue guidance to $1.48B to $1.55B and raised its adjusted EPS guidance to $1.15 to $1.35, reflecting confidence in its operational and strategic direction. Stonegate Capital Partners values NU Skin at a forward Price to Adj. EPS of 5.2x, with a valuation range suggesting significant upside potential. For more details on NU Skin's performance and strategic initiatives, visit https://www.nuskin.com.